Limited studies have described long-term outcomes in pathology confirmed multiple sclerosis (MS).
Objectives:
To describe long-term clinical–radiographic–cognitive outcomes in a prospectively followed cohort of patients with pathologically confirmed CNS demyelinating disease, consistent with MS.
Methods:
Subjects underwent clinical assessment, standardized 3T-MRI brain, and cognitive battery.
Results:
Seventy-five patients were included. Biopsied lesion size was ⩾ 2 cm in 62/75. At follow-up, median duration since biopsy was 11 years. Median EDSS was 3 and lesion burden was large (median 10 cm3). At follow-up, 57/75 met MS criteria, 17/75 had clinically isolated syndrome, and 1 radiographic changes only. Disability scores were comparable to a prevalence cohort in Olmsted County (p < 0.001, n = 218). Cognitive outcomes below age-normed standards included psychomotor, attention, working memory, and executive function domains. Total lesion volume and index lesion-related severity correlated with EDSS and cognitive performance. Volumetric cortical/subcortical GM correlated less than lesion metrics to cognitive outcomes.
Conclusion:
Despite early aggressive course in pathologically confirmed MS, its long-term course was comparable to typical MS in our study. Cognitive impairment in this group seemed to correlate strongest to index lesion severity and total lesion volume. It remains to be established how the aggressive nature of the lesion, biopsy, and treatment affect clinical/cognitive outcomes.
IkonomidouVNRichertNDVortmeyerA, et al. Evolution of tumefactive lesions in multiple sclerosis: A 12-year study with serial imaging in a single patient. Mult Scler2013; 19(11): 1539–1543.
2.
BalloyGPelletierJSuchetL, et al. Inaugural tumor-like multiple sclerosis: Clinical presentation and medium-term outcome in 87 patients. J Neurol2018; 265(10): 2251–2259.
3.
AmatoMPZipoliVPortaccioE.Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. J Neurol Sci2006; 245: 41–46.
4.
AmatoMPZipoliVPortaccioE.Cognitive changes in multiple sclerosis. Expert Rev Neurother2008; 8: 1585–1596.
5.
PittockSJMcClellandRLAchenbachSJ, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry2005; 76(12): 1693–1697.
6.
LucchinettiCFBrückWParisiJ, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol2000; 47(6): 707–717.
7.
JenkinsonMBannisterPBradyM, et al. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage2002; 17(2): 825–841.
8.
TillemaJMHulstHERoccaMA, et al. Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study. Mult Scler2016; 22: 901–909.
9.
TillemaJMWeigandSDDayanM, et al. Dark rims: Novel sequence enhances diagnostic specificity in multiple sclerosis. Am J Neuroradiol2018; 39(6): 1052–1058.
10.
MaruffPThomasECysiqueL, et al. Validity of the CogState brief battery: Relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol2009; 24(2): 165–178.
11.
LucchinettiCFGavrilovaRHMetzI, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain2008; 131(7): 1759–1775.
12.
MayrWTPittockSJMcClellandRL, et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology2003; 61: 1373–1377.
13.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
14.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
15.
LublinFDReingoldSCCohenJA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
16.
SpitzerRLKroenkeKWilliamsJB.Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA1999; 282: 1737–1744.
17.
DaleAMFischlBSerenoMI.Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage1999; 9(2): 179–194.
18.
FischlBSerenoMIDaleAM.Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. NeuroImage1999; 9(2): 195–207.
19.
WoolrichMWJbabdiSPatenaudeB, et al. Bayesian analysis of neuroimaging data in FSL. NeuroImage2009; 45(Suppl. 1): S173–S186.
20.
GreenlandS.Multiple comparisons and association selection in general epidemiology. Int J Epidemiol2008; 37(3): 430–434.
21.
ShieeNBazinPLZackowskiKM, et al. Revisiting brain atrophy and its relationship to disability in multiple sclerosis. PLoS ONE2012; 7(5): e37049.
22.
BartlettEShawMSchwarzC, et al. Brief computer-based information processing measures are linked to white matter integrity in pediatric-onset multiple sclerosis. J Neuroimaging2019; 29(1): 140–150.
23.
OuelletteRBergendalAShamsS, et al. Lesion accumulation is predictive of long-term cognitive decline in multiple sclerosis. Mult Scler Relat Disord2018; 21: 110–116.
24.
PreziosaPRoccaMAPaganiE, et al. Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study. Hum Brain Mapp2016; 37(4): 1627–1644.
25.
EijlersAJCvan GeestQDekkerI, et al. Predicting cognitive decline in multiple sclerosis: A 5-year follow-up study. Brain2018; 141: 2605–2618.
26.
HanXMTianHJHanZ, et al. Correlation between white matter damage and gray matter lesions in multiple sclerosis patients. Neural Regen Res2017; 12(5): 787–794.
HasanKMWalimuniISAbidH, et al. Multi-modal quantitative MRI investigation of brain tissue neurodegeneration in multiple sclerosis. J Magn Reson Imaging2012; 35(6): 1300–1311.
29.
GranbergTMartolaJBergendalG, et al. Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study. Mult Scler2015; 21(9): 1151–1158.
30.
Van SchependomJGielenJLatonJ, et al. The effect of morphological and microstructural integrity of the corpus callosum on cognition, fatigue and depression in mildly disabled MS patients. Magn Reson Imaging2017; 40: 109–114.
31.
YoungNPWeinshenkerBGParisiJE, et al. Perivenous demyelination: Association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain2010; 133(2): 333–348.
32.
HöftbergerRGuoYFlanaganEP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol2020; 139(5): 875–892.
33.
RoemerSFParisiJELennonVA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain2007; 130(Pt. 5): 1194–1205.
34.
WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85: 177–189.
35.
López-ChiribogaASMajedMFryerJ, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol2018; 75: 1355–1363.
